Success Metrics

Clinical Success Rate
80.0%

Based on 12 completed trials

Completion Rate
80%(12/15)
Active Trials
0(0%)
Results Posted
8%(1 trials)
Terminated
3(20%)

Phase Distribution

Ph phase_1
10
67%
Ph phase_2
5
33%

Phase Distribution

10

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
10(66.7%)
Phase 2Efficacy & side effects
5(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

12 of 15 finished

Non-Completion Rate

20.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(12)
Terminated(3)

Detailed Status

Completed12
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (66.7%)
Phase 25 (33.3%)

Trials by Status

completed1280%
terminated320%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT02273219Phase 1

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Completed
NCT00492869Phase 1

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Completed
NCT00885196Phase 2

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Completed
NCT00572585Phase 2

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Completed
NCT00615693Phase 2

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

Completed
NCT01402440Phase 1

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Terminated
NCT01430416Phase 1

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Completed
NCT01854606Phase 1

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

Completed
NCT00555789Phase 2

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

Terminated
NCT00403416Phase 1

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

Completed
NCT00545259Phase 1

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

Completed
NCT01801358Phase 1

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Terminated
NCT00504543Phase 2

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

Completed
NCT00409929Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071

Completed
NCT00416546Phase 1

Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15